Skip to main content

Stephanie Gaillard

Adjunct Assistant Professor in the Department of Medicine
Medicine, Medical Oncology
DUMC 3079, Durham, NC 27710
DUMC Box 3079, Durham, NC 27710

Overview


Dr. Stéphanie Gaillard is an Assistant Professor in Medical Oncology at the Duke Cancer Institute. Dr. Gaillard is board certified by the American Board of Internal Medicine in both Internal Medicine and Medical Oncology. At Duke, she focuses on treating patients with gynecologic malignancies and conducts basic science and clinical research. Dr. Gaillard’s laboratory research focuses on elucidating the biology of ovarian cancer, especially metabolic changes in the development of ovarian tumors, and mechanisms of resistance to chemotherapy. Her clinical research interests center on the development of novel therapeutic strategies for the treatment of ovarian cancer through early phase clinical trials. In addition to the Ovarian Cancer Research Fund Liz Tilberis Grant, Dr. Gaillard has received a Department of Defense Breast Cancer Research Program pre-doctoral research award and a Conquer Cancer Foundation Young Investigator Award.

Current Appointments & Affiliations


Adjunct Assistant Professor in the Department of Medicine · 2017 - Present Medicine, Medical Oncology, Medicine

Recent Publications


Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis

Journal Article Cancer Treatment Reviews · July 1, 2025 Background: The addition of induction chemotherapy (ICT) prior to concomitant chemoradiotherapy (CCRT) in the treatment of locally advanced cervical cancer (LACC) is controversial, as trials have yielded conflicting results. This study aims to evaluate the ... Full text Cite

A pilot study investigating the effect of pembrolizumab on the tumoral immunoprofile of newly diagnosed mullerian cancers

Journal Article Gynecologic Oncology Reports · June 1, 2025 Objective: This pilot window of opportunity study was conducted to assess feasibility, toxicity, and changes in immune parameters in response to one dose of the PD-1 inhibitor, pembrolizumab, in patients newly diagnosed with mullerian epithelial cancers. M ... Full text Cite

Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study.

Journal Article Int J Gynecol Cancer · May 2025 OBJECTIVE: Next-generation sequencing and tumor testing to direct therapy in advanced/recurrent endometrial cancer are frequently used, but the impact of this approach is unclear. We sought to confirm the proportion of patients with at least 1 actionable a ... Full text Link to item Cite
View All Publications